TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06770998

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EEG-neurofeedback training
Description: 15 training sessions (twice/week) plus two booster training sessions added to treatment as usual.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham training
Description: 15 sham sessions (twice/week) plus two sham booster sessions added to treatment as usual.
Study: NCT06772051

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Resin composite restoration bonded using universal adhesive in etch and rinse mode (15 seconds etching)
Description: Resin composite restoration bonded using universal adhesive in etch and rinse mode (15 seconds etching)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resin composite restoration bonded using universal adhesive in etch and rinse mode (5 seconds etching)
Description: Resin composite restoration bonded using universal adhesive in etch and rinse mode (5 seconds etching)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Resin composite restoration bonded using universal adhesive in self-etch mode
Description: Resin composite restoration bonded using universal adhesive in self-etch mode
Study: NCT05357131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypnosis with VR (VRH)
Description: The VRH intervention will use the Aqua video session developed by Oncomfort.
Study: NCT05332119

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR glasses
Description: Patients will watch a virtual world in VR glasses during the painful procedure. They will be able to choose between 3 VR content based on their preferences.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: Patients will not receive distraction during chest drain removal
Study: NCT06770153

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tensor
Description: balancing will be carried out using the TEMIS DePuy tensioner and carrying out any releases according to the gap-balancing technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard
Description: primary TKA implantation with ligament balancing without use of the tensioner
Study: NCT06774287

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Karman Line memory strategy training
Description: The memory strategy training consists of six weekly face-to-face treatment sessions. After sessions 3-5, the participant will play 8 levels in total of the Karman Line memory game on their computer or mobile device. In these levels they practice the strategies that are introduced in the face-to-face treatment in a safe digital environment. Also, the Karman Line memory app is provided.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual contains ten sessions, with nine obligatory sessions supplemented with 1 (of five) non-obligatory sessions. Which non-obligatory sessions is chosen is dependent on the patients treatment goals.
Study: NCT06772233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib combined with envafolimab
Description: -Regorafenib: Specification: 40 mg/tablet Dosage: 120 mg, taken orally once daily for 3 weeks, followed by 1 week off, until disease progression or intolerable toxicity occurs.~* Envafolimab:~Specification: 200 mg/vial Dosage: 200 mg, administered via subcutaneous injection once every 2 weeks, until disease progression or intolerable toxicity occurs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Select a targeted drug that has been effective in previous treatments, such as Imatinib, Sunitinib, Regorafenib, or Ripretinib. Continue the original dosage and regimen until disease progression or unacceptable toxicity occurs.
Study: NCT06772480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Patients will receive oral thalidomide starting at 50 mg daily, with a weekly increase of 50 mg up to a maximum of 200 mg daily, continued for four months

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Argon Plasma Coagulation
Description: Patients will undergo APC treatment every 2-3 weeks initially, followed by maintenance sessions every three months as required.
Study: NCT06773767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg trazodone hydrochloride
Description: To compare the bioavailability of 150 mg trazodone hydrochloride tablets (new polymer) vs. 150 mg trazodone hydrochloride Contramid® tablets at steady-state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 300 mg trazodone hydrochloride
Description: To compare the bioavailability of 300 mg trazodone hydrochloride tablets (new polymer) vs. 300 mg trazodone hydrochloride Contramid® tablets at steady-state
Study: NCT06774001

Intervention type: PROCEDURE
Intervention: Appendicectomy
Description: Both open and minimally invasive (laparoscopic and robotic) interventions are eligible for inclusion. Laparoscopic and robotic converted to open cases are also eligible.
Study: NCT06770569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-3802
Description: HRS-3802
Study: NCT06770855

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total consolidative MPDT
Description: After stopping systemic anti-cancer therapy for metastatic RCC, participant will receive one or more of the following: surgery (e.g. nephrectomy, metastasectomy, lymph node dissection), percutaneous cryoablation and/or radiotherapy (SAbR or other definitive radiotherapy).
Study: NCT06771336

Intervention type: OTHER
Intervention: Questionnaires
Description: Quality of life questionnaires, questionnaires for assessing functional results, micro-costing questionnaire, informal support assessment questionnaires
Study: NCT06773949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta burst stimulation
Description: Cool B70 cooled-coil (left DLPFC) with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)

Intervention type: DEVICE
Group type: OTHER
Intervention: Theta burst stimulation
Description: Cool B70 cooled-coil (left DLPFC) with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
Study: NCT06031389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Henagliflozin
Description: On the basis of hypoglycemic therapy, the patients in the intervention group were given the drug treatment of hengglinide, once a day, 10mg or 5mg each time, taken in the morning, for 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: On the basis of basic treatment, patients in the blank control group were given starch tablets once a day, 10mg or 5mg each time, taken in the morning for 12 months.
Study: NCT05762328

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Reminders to the assistant clinicians of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment community-acquired pneumonia
Description: Automatic reminders through pop-up windows in the computerized prescription software, reminding the clinician responsible for each patient of the need to adhere to clinical guidelines regarding the duration of antibiotic treatment in patients with clinical stability
Study: NCT06774599

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: music combined with lavender essential oil group
Description: listening of 30 mins ocean wave music, aromatherapy of lavender essential oil, and eye masks and earplugs.
Study: NCT06775145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-R_cDC+cTBS & sham-L_aDC+iTBS
Description: HD-tES inhibitory waveform (cDC+cTBS) applied to the right dorsolateral prefrontal cortex (DLPFC) for 10 minutes, followed by sham excitatory waveform (aDC+iTBS) stimulation applied to the left DLPFC for 10 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham-R_cDC+cTBS & HD-L_aDC+iTBS
Description: Sham inhibitory waveform (cDC+cTBS) stimulation applied to the right DLPFC for 10 minutes, followed by HD-tES excitatory waveform (aDC+iTBS) applied to the left DLPFC for 10 minutes.
Study: NCT06299189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MinADHD
Description: Guided self-help, 7 modules Interventions
Study: NCT06775145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-R_cDC+cTBS & HD-L_aDC+iTBS
Description: HD-tES inhibitory waveform (cDC+cTBS) applied to the right DLPFC for 10 minutes, followed by HD-tES excitatory waveform (aDC+iTBS) applied to the left DLPFC for 10 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-R_cDC+cTBS & sham-L_aDC+iTBS
Description: Sham inhibitory waveform (cDC+cTBS) stimulation applied to the right DLPFC for 10 minutes, followed by sham excitatory waveform (aDC+iTBS) stimulation applied to the left DLPFC for 10 minutes.
Study: NCT06770491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-3 for injection
Description: The investigational drug (Y-3) consists of two parts: Y-3 for injection (lyophilized powder) and Solvent for Y-3 for injection (concentrated solution).~Name: Y-3 for injection Strength: 20 mg Dosage Form: Lyophilized powder for injection Storage Condition: 2-8°C Supplier: Neurodawn Pharmaceutical Co., Ltd. Name: Reconstitution diluent for Y-3 for injection Strength: 3ml (containing 0.6 g propylene glycol) Dosage Form: Concentrated solution for injection Storage Condition: 2-8°C Supplier: Neurodawn Pharmaceutical Co., Ltd.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consists of two parts: placebo (lyophilized powder) and Solvent for Y-3 for injection(concentrated solution).~Name: Placebo Strength: 0 mg Dosage Form: Lyophilized powder for injection Storage Condition: 2-8°C Supplier: Neurodawn Pharmaceutical Co., Ltd. Name: Solvent for Y-3 for injection Strength: 3 mL (containing 0.6 g propylene glycol) Dosage Form: Concentrated solution for injection Storage Condition: 2-8°C Supplier: Neurodawn Pharmaceutical Co., Ltd.
Study: NCT06774443

Intervention type: OTHER
Intervention: Neuropsychological assessment
Description: Neuropsychological assessment consisting of tests measuring social cognition and memory
Study: NCT06774066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High volume image guided injection
Description: High volume image guided injection consists of 9.5ml of bupivacaine, 0.5ml 20mg Depo-medrol, and 40ml of injectable saline. This procedure will be commenced with a thorough disinfection of the injection site. The mid-portion of the Achilles tendon will then be imaged in the short axis to obtain a cross-sectional view of the tendon, alongside the anterior region, including Kager's fat pad, particularly in areas of maximal pain and increased neovascularity. Once the needle is correctly positioned, the high-volume fluid will be infiltrated under pressure, with ultrasound guidance confirming the reduction or complete disappearance of neovascularisation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive rehabilitation exercise programme
Description: A comprehensive explanation of the progressive exercise program will be provided to patients, along with a detailed booklet that includes four tiers of exercises, ranging from the easiest to the most challenging. Exercises include several eccentrics, isometrics and heavy slow resistance exercises. These exercises are to be performed once a day and the intensity and number of repetitions will be based on the patients' status. The progressive exercise program is designed to avoid exacerbating the patient's symptoms; however, some pain is permitted during the sessions following the pain monitoring model proposed by Thomee (1997)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive rehabilitation exercise programme
Description: A comprehensive explanation of the progressive exercise program will be provided to patients, along with a detailed booklet that includes four tiers of exercises, ranging from the easiest to the most challenging. Exercises include several eccentrics, isometrics and heavy slow resistance exercises. These exercises are to be performed once a day and the intensity and number of repetitions will be based on the patients' status. The progressive exercise program is designed to avoid exacerbating the patient's symptoms; however, some pain is permitted during the sessions following the pain monitoring model proposed by Thomee (1997)
Study: NCT06771063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WXSH0102/placebo
Description: Administer WXSH0102 tablets/placebo orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WXSH0102/placebo
Description: Administer WXSH0102 tablets/placebo orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WXSH0102/placebo
Description: Administer WXSH0102 tablets/placebo orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluconazole capsules/placebo
Description: Administer fluconazole capsules/placebo orally
Study: NCT06771037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Neurostimulation (tAN)
Description: Transcutaneous Auricular stimulation will be delivered using the Spark Biomedical Sparrow Link pulse generator with Sparrow Ascent earpieces. The Sparrow Link generator is based on FDA-cleared predicate Sparrow Ascent.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Auricular Neurostimulation (tAN)
Description: Transcutaneous Auricular stimulation will be delivered using the Spark Biomedical Sparrow Link pulse generator with Sparrow Ascent earpieces. The Sparrow Link generator is based on FDA-cleared predicate Sparrow Ascent.
Study: NCT06774807

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline/Placebo
Description: NaCl (9mg/ml)
Study: NCT05429086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam combined propofol
Description: Remimazolam combined propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remimazolam
Description: remimazolam only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: propofol only
Study: NCT05836233

Intervention type: DRUG
Intervention: Pulmonary Vasodilators
Description: Right heart catheterization via Swan Ganz catether will be performed under optimal medical therapy within 90 days before LVAD implantation. We will record the timing between RHC and LVAD implantation.~Vasodilator challenge will be performed through intravenous nitroprusside administration and titration (by 5 minutes intervals) until symptoms (flushing or hypotension) onset or systolic systemic pressure drop below 85 mmHg (target dose).~Dobutamine or phosphodiesterase inhibitors infusion could be performed at clinician's discretion.~All haemodynamic measurements will be repeated after nitroprusside infusion and titration until the target dose.
Study: NCT06774807

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Agonist/Saline
Description: GLP-2(1-33)/Saline (9mg/ml)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Agonist/1Antagonist
Description: GLP-2 (1-33)/GLP-2(3-33) 1 nmol/kg/min

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Agonist/4Antagonist
Description: GLP-2 (1-33)/GLP-2 (3-33) 4 nmol/kg/min
Study: NCT06770686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: A nursing care bundle will be applied to patients in the intervention group. The implementation status of the nursing interventions included in the care bundle for each patient will be observed by the researcher and recorded on the Care Bundle Observer Form. Recording of the applications performed on the monitoring form will be encouraged.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: They will receive standard care
Study: NCT06774664

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SCTC21C
Description: Drug: SCTC21C Administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTC21C
Description: Drug: SCTC21C Administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTC21C
Description: Drug: SCTC21C Administered SC

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SCTC21C
Description: Drug: SCTC21C Administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTC21C
Description: Drug: SCTC21C Administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTC21C
Description: Drug: SCTC21C Administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTC21C
Description: Drug: SCTC21C Administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTC21C
Description: Drug: SCTC21C Administered SC

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SCTC21C
Description: Drug: SCTC21C Administered SC

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SCTC21C
Description: Drug: SCTC21C Administered SC
Study: NCT06769997

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optilume® BPH Catheter System
Description: The technology is based on a device/drug combination consisting of two catheters: the Optilume BPH Prostatic Pre-dilation Catheter which is a non-drug coated catheter used to start commissurotomy between the lateral lobes of the prostate and the Optilume BPH Prostatic Dilatation DCB Catheter which is a drug coated catheter used to complete the commissurotomy and transfers drug (paclitaxel) to the pre-dilated prostatic urethra and anterior commissure. Hence, the device applies a mechanical dilatation to open prostatic urethral lumen to increase urine flow, followed by the transfer of paclitaxel drug to inhibit cell proliferation and maintain this dilatation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rezum Water Vapor Therapy
Description: The Rezum system is minimally invasive therapy for LUTS secondary to BPH. The system injects water vapor at 103°C generated by radiofrequency to create thermal energy via a transurethral approach. The vapor disperses through the tissue interstices within the treatment zone (transition zone). The injection of vapor last for approximatively 9 seconds and the number of injections depends on the prostate volume and length of the prostatic urethra.
Study: NCT06774274

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine infusion
Description: A 10% ketamine solution will be prepared in a 250 cc bag of 0.9% saline (1 mg/cc) using 5 cc from a vial of ketamine that has a concentration of 50 mg/cc. The infusion will be initiated at the time of surgical site closure and will proceed as follows: a bolus of 0.35 cc/kg (equivalent to 0.35 mg/kg) will be administered, followed by a continuous infusion of 0.1 cc/kg/h (equivalent to 0.1 mg/kg/h) for up to 48 hours postoperatively.~Patients in this group will have access to a PCA pump with morphine for analgesic rescue and to monitor daily opioid consumption.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCA Ketamine
Description: A mixture of 5% ketamine and 5% morphine will be prepared in a 100 cc bag of 0.9% saline. This will be achieved by using 1 cc of a ketamine vial (50 mg/cc) and 5 cc of a morphine ampule (10 mg/cc). This results in a final concentration of 0.5 mg of ketamine and 0.5 mg of morphine per cc in the 100 cc saline bag.~The pump settings will be configured as follows:~* PCA (Patient-Controlled Analgesia) dose: 2 cc (which delivers 1 mg of ketamine and 1 mg of morphine)~* Lockout interval: 6 minutes~* Maximum dose limit: 15 doses over a 4-hour period~The pump will be available for patient use for up to 48 hours postoperatively.
Study: NCT06773780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local infiltration
Description: The block procedure will be performed before the surgical procedure, following the induction of sedoanalgesia. Under sterile conditions, 30 mL of 0.25% bupivacaine will be administered to the targeted infiltration area. The local anesthetic will be specifically applied around the arterial and venous puncture sites.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PENG
Description: With the patient in the supine position, a convex ultrasound (US) probe (4-8 MHz, Vivid Q) will be covered with a sterile sheath. An 80-mm block needle (Braun 360°) will be used. The probe will be placed transversely over the anterior inferior iliac spine. Subsequently, the probe will be rotated 45 degrees to visualize the pubic ramus. Once the femoral artery, iliopubic eminence, and psoas muscle are identified under ultrasound guidance, the needle will be advanced using an in-plane technique and positioned between the pubic ramus and the psoas tendon. After confirming the block site with 5 mL of saline, 30 mL of 0.25% bupivacaine will be injected as the local anesthetic.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FİB
Description: The patient's legs will be positioned slightly externally rotated. A high-frequency ultrasound probe will be placed transversely along the inguinal ligament. Under ultrasound guidance, the femoral artery, iliopsoas muscle, and fascia iliaca will be identified. The needle will be advanced parallel to the ultrasound probe using the in-plane technique and positioned beneath the fascia iliaca. After confirming negative aspiration, 30 mL of 0.25% bupivacaine will be injected, and the spread of the solution beneath the fascia iliaca will be verified using ultrasound.
Study: NCT06770465

Intervention type: DRUG
Intervention: Different categories of antibiotics
Description: Use of different categories of antibiotics during pregnancy, such as quinolones and macrolides.

Intervention type: DRUG
Intervention: Different categories of antibiotics
Description: Use of different categories of antibiotics during pregnancy, such as quinolones and macrolides.
Study: NCT06772181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardio fitness, Yoga, Tai Chi, Qigong, Dance Cardio, Guided Meditation, Music Therapy
Description: Participate in the IM@Home program delivered via Zoom

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear a FitBit activity tracker

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear a FitBit activity tracker

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete PRO surveys

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete PRO surveys
Study: NCT06772350

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: examinations
Description: Echo-Doppler and blood samples